Acute lymphoblastic leukaemia - PubMed (original) (raw)
Review
Acute lymphoblastic leukaemia
Ching-Hon Pui et al. Lancet. 2008.
Abstract
Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while reducing the toxic side-effects of current intensive regimens. Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease. Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.
Similar articles
- [A brief history of treatments for childhood acute lymphoblastic leukaemia].
Leverger G, Baruchel A, Schaison G. Leverger G, et al. Bull Acad Natl Med. 2009 Oct;193(7):1495-9; discussion 1499-500. Bull Acad Natl Med. 2009. PMID: 20669630 French. - Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia.
Rubnitz JE, Pui CH. Rubnitz JE, et al. Cancer Treat Rev. 2003 Feb;29(1):31-44. doi: 10.1016/s0305-7372(02)00106-8. Cancer Treat Rev. 2003. PMID: 12633578 Review. - New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
Pui CH, Jeha S. Pui CH, et al. Nat Rev Drug Discov. 2007 Feb;6(2):149-65. doi: 10.1038/nrd2240. Nat Rev Drug Discov. 2007. PMID: 17268486 Review. - Acute lymphoblastic leukaemia.
Inaba H, Greaves M, Mullighan CG. Inaba H, et al. Lancet. 2013 Jun 1;381(9881):1943-55. doi: 10.1016/S0140-6736(12)62187-4. Epub 2013 Mar 22. Lancet. 2013. PMID: 23523389 Free PMC article. Review. - Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG, Venzon D, Raina V. Magrath I, et al. Eur J Cancer. 2005 Jul;41(11):1570-83. doi: 10.1016/j.ejca.2004.11.004. Epub 2005 Jan 5. Eur J Cancer. 2005. PMID: 16026693 Review.
Cited by
- Similar Survival But Less Chronic GVHD in Antithymocyte Globulin-Based Myeloablative Haploidentical Transplant Compared With Matched Sibling Transplant for Adult T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Gu Z, Li F, Li M, Zhang L, Xu S, Wang L, Wang L, Jing Y, Bo J, Gao C, Dou L, Liu D. Gu Z, et al. Cell Transplant. 2024 Jan-Dec;33:9636897241270401. doi: 10.1177/09636897241270401. Cell Transplant. 2024. PMID: 39219184 Free PMC article. - Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission.
Atilano-Miguel S, Barbosa-Cortés L, Ortiz-Muñiz R, Maldonado-Hernández J, Martin-Trejo JA, Rodríguez-Cruz M, Balcázar-Hernández L, Solís-Labastida KA, Bautista-Martínez BA, Juárez-Moya A, Hernández-Piñón Z, Galindo-Rodríguez RA, Chávez-Anaya A, Valdez-Avilez RE, Domínguez-Salgado JM, Villa-Morales J, Rodríguez-Palacios ME. Atilano-Miguel S, et al. Cancers (Basel). 2024 Aug 10;16(16):2811. doi: 10.3390/cancers16162811. Cancers (Basel). 2024. PMID: 39199584 Free PMC article. - T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers.
Schoenfeld K, Habermann J, Wendel P, Harwardt J, Ullrich E, Kolmar H. Schoenfeld K, et al. Mol Ther Oncol. 2024 Jul 19;32(3):200850. doi: 10.1016/j.omton.2024.200850. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39176070 Free PMC article. - Survival Outcomes in Older Adult Acute Lymphoblastic Leukemia Patients Analyzed by Facility Volume and Type: A National Cancer Database Analysis.
Dykes KC, Chou J, Taylor AO, Shu AC, Mudra SE, Ma X, Ahn J, Lai CE. Dykes KC, et al. Cancer Rep (Hoboken). 2024 Aug;7(8):e2162. doi: 10.1002/cnr2.2162. Cancer Rep (Hoboken). 2024. PMID: 39118243 Free PMC article. Spanish. - Exploring the potential of IL-10 for risk assessment and early intervention in pediatric ALL.
Radwan RE, Darwish A, Elsaid AM, El-Kholy WM. Radwan RE, et al. BMC Cancer. 2024 Aug 8;24(1):972. doi: 10.1186/s12885-024-12677-w. BMC Cancer. 2024. PMID: 39118076 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA68484/CA/NCI NIH HHS/United States
- NR07610/NR/NINR NIH HHS/United States
- CA36401/CA/NCI NIH HHS/United States
- CA90246/CA/NCI NIH HHS/United States
- CA52259/CA/NCI NIH HHS/United States
- CA60419/CA/NCI NIH HHS/United States
- GM61393/GM/NIGMS NIH HHS/United States
- CA06516/CA/NCI NIH HHS/United States
- CA51001/CA/NCI NIH HHS/United States
- P30 CA006516/CA/NCI NIH HHS/United States
- CA21765/CA/NCI NIH HHS/United States
- CA78224/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous